A phase III study of Eryaspase for pancreatic cancer
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2017
At a glance
- Drugs ERY-ASP (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 11 Sep 2017 According to an ERYtech Pharma media release, the company expects the potential launch of this study over next twelve months.
- 11 Sep 2017 According to an ERYtech Pharma media release, the company expects to discuss the design of this potential phase 3 study with the U.S. FDA in the coming weeks (scheduled for October) and the Committee for Medicinal Products for Human Use (CHMP) before the end of the year (later in 2017).
- 05 Jun 2017 New trial record